Bausch + Lomb Corporation (NYSE: BLCO ) on Monday announced plans to push two first-in-class ophthalmic pipeline assets into advanced clinical testing following data from recent human trials .
The pipeline programs target dry eye disease and ocular surface pain, representing a combined estimated peak sales potential exceeding $2 billion.
Dry Eye Combination Prepares For Phase 3
The company’s dual-action eye drop combines active ingredients from XIIDRA and MIEBO into a single twice-daily therapy.
In a Phase 2 trial of 443 patients, the candidate missed its Day 29 primary endpoint for superior corneal staining reduction over lifitegrast alone.
However, it achieved a statistically significant reduction at Day 15 (p=0.0007), where 41.6% of patients achieved marked improvement compared to 18.8% on lifitegrast alone.
Read Next MoversBausch + Lomb Ends Glaucoma Drug Development, Shifts Focus
Bausch + Lomb ended BL1107 glaucoma eye drop development after a Phase 2 miss and will focus on a sustained-release GA implant.
2 min read Read this articleUsing over 50% less lifitegrast volume than XIIDRA and half the dosing frequency of MIEBO, the candidate maintained a safety profile consistent with both established drugs .
Trending Get a 1% Match on Your First Deposit of $1,000+Bausch + Lomb will advance the treatment to Phase 3 studies using the FDA-accepted Day 15 primary endpoint. The asset carries an estimated peak sales projection of $700 million.
Ocular Pain Asset Delivers Phase 1b Results
Meanwhile, BL1332, a novel TRPV1 antagonist targeting ocular surface pain, met its primary endpoint in a Phase 1b trial.
Treated eyes experienced a 5.5-point drop in pain intensity five seconds after a capsaicin challenge compared to vehicle (p
Bausch + Lomb is evaluating BL1332 in a Phase 2 post-surgical study, expecting topline data in the coming months. Management targets BL1332 peak sales at $1.4 billion, expecting both assets to drive growth past 2028 .
Earnings Snapshot
On July 29, Bausch + Lomb reported second-quarter adjusted earnings of 16 cents per share, beating the 15-cent estimate. Sales of $1.394 billion also topped the $1.369 billion estimate .
The company raised its 2026 sales outlook to $5.44 billion to $5.54 billion from $5.42 billion to $5.52 billion. The midpoint is above the $5.468 billion estimate.
BLCO Stock Price Activity: Bausch & Lomb shares were up 1.04% at $17.50 during premarket trading on Tuesday, according to Benzinga Pro data .
Image via Shutterstock
Read Next MarketsNvidia Manager Named ‘Key Figure’ in Alleged B300 GPU Smuggling to China, 8 Others Indicted in Taiwan Probe
Nvidia manager named a key figure in alleged illicit B300 GPU exports to China as Taiwan indicts nine in AI chip probe.
2 min read Read this article Market News and Data brought to you by Benzinga APIs© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
To add Benzinga News as your preferred source on Google, click here .
Posted In: Movers News General Top Stories Health Care Large Cap Why It's Moving